{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:55Z","timestamp":1777420975227,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, pharmacokinetics, safety, and efficacy of bempedoic acid for low-density lipoprotein cholesterol (LDL-C) reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A PubMed search was conducted from January 2000 to June 15, 2020, using the keyword bempedoic acid for phase III clinical trials published in the English language.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles related to the Food and Drug Administration (FDA) approval of bempedoic acid and other trials relating to the safety and efficacy of this drug were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The findings from this review show that bempedoic acid is a safe and effective option for lowering LDL-C levels in patients requiring LDL-C lowering for primary or secondary prevention of cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Statin therapy remains the mainstay of treatment for both primary and secondary prevention. However, many patients cannot tolerate statin therapy because of statin-associated muscle symptoms. Bempedoic acid may be a reasonable adjunct for LDL-C reduction, though further evaluation of cardiovascular outcomes with bempedoic acid in this population is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The recent FDA approval of bempedoic acid offers an additional option for lowering LDL-C levels in patients with atherosclerotic cardiovascular disease or heterozygous familial hyperlipidemia. Additional data regarding effect on long-term cardiovascular outcomes with bempedoic acid are currently being studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020941083","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:12:48Z","timestamp":1594959168000},"page":"246-251","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Bempedoic Acid: A New Drug for an Old Problem"],"prefix":"10.1177","volume":"55","author":[{"given":"Dat","family":"Nguyen","sequence":"first","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Du","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M.","family":"Sulaica","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-8200","authenticated-orcid":false,"given":"Matthew A.","family":"Wanat","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"bibr1-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625"},{"key":"bibr2-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"bibr3-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"bibr4-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.01.006"},{"key":"bibr5-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003626"},{"key":"bibr6-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.09.075"},{"key":"bibr7-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.05.007"},{"key":"bibr8-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600176"},{"key":"bibr9-1060028020941083","unstructured":"Nexletol. Package insert. Esperion Therapeutics, Inc; 2020. Revised February 2020. Accessed April 11, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf"},{"key":"bibr10-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"bibr11-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662"},{"key":"bibr12-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803917"},{"key":"bibr13-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16585"},{"key":"bibr14-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"bibr15-1060028020941083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020941083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:42Z","timestamp":1777374942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020941083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/1060028020941083"],"URL":"https:\/\/doi.org\/10.1177\/1060028020941083","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}